These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 29735917)

  • 1. Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.
    Shi T; Ma Y; Yu L; Jiang J; Shen S; Hou Y; Wang T
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29735917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic Immunotherapy.
    Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
    Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus.
    Farrera-Sal M; Moya-Borrego L; Bazan-Peregrino M; Alemany R
    Clin Cancer Res; 2021 Jun; 27(11):2979-2988. PubMed ID: 33526422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
    Rajani KR; Vile RG
    Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Turning Cold into Hot: Firing up the Tumor Microenvironment.
    Duan Q; Zhang H; Zheng J; Zhang L
    Trends Cancer; 2020 Jul; 6(7):605-618. PubMed ID: 32610070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
    Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
    Front Immunol; 2019; 10():1848. PubMed ID: 31440242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.
    Malogolovkin A; Gasanov N; Egorov A; Weener M; Ivanov R; Karabelsky A
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34209981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SnapShot: Cancer Immunotherapy with Oncolytic Viruses.
    Gujar S; Bell J; Diallo JS
    Cell; 2019 Feb; 176(5):1240-1240.e1. PubMed ID: 30794777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review).
    Wang X; Zhong L; Zhao Y
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33760203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
    Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
    EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virus-induced cell death and immunity: a match made in heaven?
    De Munck J; Binks A; McNeish IA; Aerts JL
    J Leukoc Biol; 2017 Sep; 102(3):631-643. PubMed ID: 28720686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.
    Niemann J; Woller N; Brooks J; Fleischmann-Mundt B; Martin NT; Kloos A; Knocke S; Ernst AM; Manns MP; Kubicka S; Wirth TC; Gerardy-Schahn R; Kühnel F
    Nat Commun; 2019 Jul; 10(1):3236. PubMed ID: 31324774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of NK cells in immunotherapy and virotherapy of solid tumors.
    Cantoni C; Grauwet K; Pietra G; Parodi M; Mingari MC; De Maria A; Favoreel H; Vitale M
    Immunotherapy; 2015; 7(8):861-82. PubMed ID: 26314197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
    Cavalcante L; Chowdhary A; Sosman JA; Chandra S
    Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.